The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Dechert LLP

1095 AVENUE OF THE AMERICAS, NEW YORK, NY 10036-6797, USA
Tel:
Work +1 212 698 3500
Fax:
Fax +1 212 698 3599
Email:
Web:
www.dechert.com

David S Rosenthal

Tel:
Work +1 212 698 3616
Email:
Dechert LLP

Work Department

Corporate

Career

David S. Rosenthal, co-chair of Dechert’s Global Corporate Finance and Capital Markets practice, represents publicly and privately held corporations, investment banks, and venture capital firms focused on the life sciences and medical device, technology, media, and other growth sectors. He represents clients in corporate finance transactions, mergers and acquisitions, joint ventures, licensings and strategic alliances.

Education

Wesleyan University, B.A., 1978, cum laude; Boston University School of Law, J.D., 1981, cum laude


United States: Finance

Capital markets: debt offerings

Within: Capital markets: debt offerings

Dechert LLP has an active debt practice, which stands out for its niche expertise in life sciences and permanent capital vehicles, especially business development companies. In a recent example of its work in this area, Philadelphia-based partners Kenneth Young and Gregory Schernecke advised business development company Corporate Capital Trust on a private offering of $140m of senior notes. Boston-based corporate finance specialist Thomas Friedmann co-chairs the capital markets group and assisted Eagle Point Credit Company with several recent deals, including handling its $31.6m public notes offering. David Rosenthal co-chairs the department from New York.

[back to top]

Capital markets: equity offerings

Within: Capital markets: equity offerings

At Dechert LLP, Boston-based group co-head Thomas Friedmann is well known for his specialist skill set in acting for business development companies. In a recent example, Friedmann advised Eagle Point Credit on its $30.3m public offering. The firm is also active on behalf of underwriters, with Philadelphia-based partners James Lebovitz and Gregory Schernecke advising the underwriters on Amicus Therapeutics’ $258.8m public offering. David Rosenthal co-leads the practice from New York and with Schernecke acted for the joint book-running managers on Inovio Pharmaceuticals’ $75m public offering. Other key clients include Franklin Square Capital Partners, Golub Capital and Stifel Nicolaus.

[back to top]

Capital markets: global offerings

Within: Capital markets: global offerings

Dechert LLP’s strong focus on life sciences and permanent capital vehicles ensures a steady stream of work for clients in those areas. Among its work for the latter, Philadelphia-based partners Kenneth Young and Gregory Schernecke assisted business development company Corporate Capital Trust with its $140m private notes offering. Elsewhere, New York’s David Rosenthal, acting with the Paris office, advised the joint lead managers and book-runners on Biom’Up’s €38.1m IPO in Paris.

[back to top]

Capital markets: high-yield debt offerings

Within: Capital markets: high-yield debt offerings

Dechert LLP houses a robust issuer-side practice, which has specialist expertise in advising life sciences companies and permanent capital vehicles. Boston-based Thomas Friedmann co-heads the department and led advice to Eagle Point Credit Company on several deals over the past year, including on its $31.6m notes offering. Stephen Leitzell - who is a key name in Philadelphia - advised B&G Foods on a $500m notes offering. New York’s David Rosenthal co-chairs a team that also includes James Lebovitz and newly made-up partner Gregory Schernecke - both of whom operate from Philadelphia.

[back to top]

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

At Dechert LLP, the group is known for its expertise in patent litigation, as well as regulatory and transactional matters. In Philadelphia, George Gordon, who specializes in antitrust matters, has been defending Lannett Company against price-fixing claims, while Martin Black successfully represented Svenska Cellulosa (SCA) in a patent infringement dispute regarding the client’s hygiene product. Boston-based practice co-chair Andrea Reid assisted Nimbus Therapeutics with the development and implementation of a patent portfolio strategy regarding a program for patients with autoimmune disorders. The group is also led by New York-based David Rosenthal and also includes David Schulman in Washington DC.

[back to top]


Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to